To improve the clinical tolerability, we simultaneously evaluated the splicing of SMN2 and secondary splice targets (e.g., FOXM1) in SMA patient-derived fibroblasts, which maintain the intrinsic structure of cellular mRNAs. Here, SMN2 is linked to proximal spinal muscular atrophy.